🤯 Did You Know (click to read)
The 2021 UCL study was published in The New England Journal of Medicine, one of the world’s most cited medical journals.
In 2021, researchers at University College London conducted a randomized clinical trial comparing psilocybin-assisted therapy with the antidepressant escitalopram for major depressive disorder. The study, published in The New England Journal of Medicine, involved two supervised psilocybin sessions alongside psychological support. Participants in the comparison group received daily escitalopram with identical therapeutic contact time. Outcomes were measured using standardized depression rating scales over six weeks. Both groups showed improvement, with certain secondary measures favoring the psilocybin group. The trial did not claim superiority on its primary endpoint but demonstrated comparable efficacy within controlled conditions. The molecule originating in dung-fed fungi entered direct comparison with a widely prescribed selective serotonin reuptake inhibitor. That juxtaposition would have been implausible in mainstream medicine two decades earlier.
💥 Impact (click to read)
The trial signaled a regulatory and scientific shift. Psilocybin research had been largely dormant due to legal restrictions. Reintroduction into high-tier journals reflects growing institutional willingness to reassess psychedelic compounds. Pharmaceutical economics also play a role, as treatment-resistant depression represents a significant healthcare burden. The study design incorporated blinding, control groups, and standardized measures to meet modern evidence thresholds. A wild mushroom derivative was evaluated using the same methodological rigor applied to patented medications.
For patients, the comparison reframes assumptions about what constitutes legitimate medicine. Escitalopram is manufactured in controlled pharmaceutical facilities, while psilocybin originates in soil-based fungal metabolism. Yet both interact with serotonin systems in the brain. The contrast challenges cultural boundaries between natural and synthetic therapies. Clinical context, not origin story, determines safety and outcome. A molecule once seized in police evidence lockers now appears in peer-reviewed treatment algorithms.
💬 Comments